Net income for Thousand Oaks biotech giant Amgen fell 8 percent for the third quarter to $1.86 billion, but revenue and earnings per share both saw an uptick, spurred by strong new product sales and share buybacks. Product sales increased 1 percent overall compared to the same period the prior year, the company reported Oct.…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
